Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Avatrombopag

Venous thromboembolism following off-label use

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shao L, et al. A Single Institutional Experience Using Avatrombopag to Manage Severe and Refractory Treatment Related Thrombocytopenia in Solid Tumor and Hematologic Malignancy Patients. Blood 142 (Suppl. 1): 5447, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-188831 [abstract] Shao L, et al. A Single Institutional Experience Using Avatrombopag to Manage Severe and Refractory Treatment Related Thrombocytopenia in Solid Tumor and Hematologic Malignancy Patients. Blood 142 (Suppl. 1): 5447, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-188831 [abstract]
Metadaten
Titel
Avatrombopag
Venous thromboembolism following off-label use
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53936-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Secukinumab

Case report

Cetuximab